Urolithin A supplement before prostate cancer surgery
Part of Cancer clinical trials.
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by a biopsy within the last 6 months.
- You are scheduled to have prostate removal surgery in the next 3 to 6 weeks.
- You have not had any previous surgery, radiation, or hormone therapy for prostate cancer.
- You are 18 years or older.
- You are not currently taking urolithin A (Mitopure) or pomegranate supplements.
- You do not have active alcohol or drug dependency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new enzalutamide implant (Enolen) placed in the prostate before surgery to see if it helps treat early prostate cancer. It is for men who are already planning to have their prostate removed.
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
This trial tests a short course of 'epigenetic therapy' (drugs that change how genes work) given before prostate removal surgery. The goal is to see if it can improve treatment effects and help shrink or control the tumor.
This trial tests two oral hormone drugs (darolutamide and relugolix) given before prostate removal surgery for men with high-risk prostate cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
This trial tests adding a natural supplement called urolithin A to standard first-line immunotherapy for people with newly diagnosed solid tumors who have not yet had any cancer treatment. The goal is to see if it makes the immunotherapy work better.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.